Treatment of bipolar disorder

Independent Drug-Pricing Assessment Finds Vascepa® (icosapent ethyl) Cost-Effective as an Adjunct to Statins in Treating Patients at High Risk of Cardiovascular Events, such as Heart Attack, Stroke and Cardiac Death

Retrieved on: 
Thursday, October 17, 2019
Organic compounds, Lipid metabolism disorders, Chemistry, Biochemistry, Ethyl eicosapentaenoic acid, Polyolefins, Treatment of bipolar disorder, Hypertriglyceridemia, Triglyceride, Amarin Corporation

However, despite the reports positive conclusion that Vascepa is cost-effective, we believe that it understates the true value of Vascepa.

Key Points: 
  • However, despite the reports positive conclusion that Vascepa is cost-effective, we believe that it understates the true value of Vascepa.
  • Our goal is to make Vascepa accessible to as many patients as possible who can benefit.
  • Vascepa is currently approved in the United States as an adjunct to diet to reduce triglyceride levels in adult patients with severe (500 mg/dL) hypertriglyceridemia.
  • Patients should be advised to swallow Vascepa capsules whole; not to break open, crush, dissolve, or chew Vascepa.

Clarify Medical Home Light Therapy System to be Exhibited at the 2019 Fall Clinical Dermatology Conference in Las Vegas

Retrieved on: 
Tuesday, October 15, 2019
Health, Medical devices, Technology, Other Health, Mobile, Wireless, Software, Hardware, Health, Medicine, Circadian rhythm, Psoriasis, Light therapy, Neonatology, Treatment of bipolar disorder, Therapy, Dermatology

Clarify Medical will feature the Clarify Medical Home Light Therapy System, its connected home phototherapy system for the treatment and monitoring of chronic skin conditions, at the Fall Clinical Dermatology Conference in Las Vegas, NV October 17-20.

Key Points: 
  • Clarify Medical will feature the Clarify Medical Home Light Therapy System, its connected home phototherapy system for the treatment and monitoring of chronic skin conditions, at the Fall Clinical Dermatology Conference in Las Vegas, NV October 17-20.
  • The treatment regimen is prescribed by the patients physician but monitored and controlled by the Clarify System, enabling patients to administer treatment with clinical precision in the convenience of their homes.
  • Clarify will be demonstrating the Home Light Therapy System at the Fall Clinical Dermatology Conference at the Wynn Las Vegas October 17-20.
  • Its Clarify Home Light Therapy System is now available nationally in the US.

Evolve Treatment Centers Joins Silicon Valley Pride Parade

Retrieved on: 
Monday, September 16, 2019
Psychiatry, Health, Articles, Drug rehabilitation, Deinstitutionalisation, Psychiatric Services, Partial hospitalization, Treatment of bipolar disorder, Residential treatment center, Mental health

SAN JOSE, Calif., Sept. 16, 2019 (GLOBE NEWSWIRE) -- To demonstrate support for LGBTQ+ adolescents in the community, Evolve Treatment Centers for Teens participated in this years Silicon Valley Pride Parade and Festival on August24thand 25that Plaza de Csar Chvez Park in Downtown San Jose.

Key Points: 
  • SAN JOSE, Calif., Sept. 16, 2019 (GLOBE NEWSWIRE) -- To demonstrate support for LGBTQ+ adolescents in the community, Evolve Treatment Centers for Teens participated in this years Silicon Valley Pride Parade and Festival on August24thand 25that Plaza de Csar Chvez Park in Downtown San Jose.
  • There was interest from teens, parents of struggling youth, and our adolescent mental health partners in Silicon Valley, said Ross.
  • Evolve Treatment Centers, accredited by CARF and The Joint Commission, offersthe highest caliber of care for teens, 12 to 17 years old, who struggle with mental health, substance abuse or behavioral issues.
  • Evolve offers a full continuum of care, including Intensive Outpatient (IOP), Partial Hospitalization (PHP), and Residential Treatment Centers (RTC).

US Bipolar Disorder Market and Competitive Landscape 2019-2024: Treatments, Pipeline, Epidemiology, Marketed Drugs, Size, Sales, Competitive Landscape

Retrieved on: 
Tuesday, September 3, 2019
Bipolar disorder, Mood disorders, Psychiatry, Depression, Psychiatric diagnosis, RTT, Human behavior, Treatment of bipolar disorder, Psychology, Bipolar

DUBLIN, Sept. 3, 2019 /PRNewswire/ -- The "US Bipolar Disorder Market and Competitive Landscape - 2019" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Sept. 3, 2019 /PRNewswire/ -- The "US Bipolar Disorder Market and Competitive Landscape - 2019" report has been added to ResearchAndMarkets.com's offering.
  • US Bipolar Disorder Market and Competitive Landscape Highlights - 2019, provides comprehensive insights into Bipolar Disorder pipeline products, Bipolar Disorder epidemiology, Bipolar Disorder market valuations and forecast, Bipolar Disorder drugs sales and competitive landscape in the US.
  • Bipolar Disorder pipeline: Find out the products in clinical trials for the treatment of Bipolar Disorder by development phase 3, phase 2, and phase 1, by pharmacological class and companies developing the products
    Bipolar Disorder drugs: Identify key products marketed and prescribed for Bipolar Disorder in the US, including trade name, molecule name, and company
    Bipolar Disorder market valuations: Find out the market size for Bipolar Disorder drugs in 2018 in the US.
  • Find out how the market advanced from 2014 and forecast to 2024
    Bipolar Disorder drugs market share: Find out the market shares for key Bipolar Disorder drugs in the US
    Evaluate commercial market opportunity assessment, positioning, and segmentation for Bipolar Disorder products

The United States Bipolar Disorder Market & Competitive Landscape Report 2019 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, June 26, 2019
Pharmaceutical, Health, Mental health, Abnormal psychology, Mood disorders, Psychiatry, Emotion, Depression, Psychiatric diagnosis, RTT, Bipolar disorder, Treatment of bipolar disorder, Bipolar

The "US Bipolar Disorder Market and Competitive Landscape - 2019" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "US Bipolar Disorder Market and Competitive Landscape - 2019" report has been added to ResearchAndMarkets.com's offering.
  • This latest research provides comprehensive insights into Bipolar Disorder pipeline products, Bipolar Disorder epidemiology, Bipolar Disorder market valuations and forecast, Bipolar Disorder drugs sales and competitive landscape in the US.
  • Bipolar Disorder pipeline: Find out the products in clinical trials for the treatment of Bipolar Disorder by development phase 3, phase 2, and phase 1, by pharmacological class and companies developing the products
    Bipolar Disorder drugs: Identify key products marketed and prescribed for Bipolar Disorder in the US, including trade name, molecule name, and company
    Bipolar Disorder market valuations: Find out the market size for Bipolar Disorder drugs in 2018 in the US.
  • Find out how the market advanced from 2014 and forecast to 2024
    Bipolar Disorder drugs market share: Find out the market shares for key Bipolar Disorder drugs in the US
    Evaluate commercial market opportunity assessment, positioning, and segmentation for Bipolar Disorder products

CCHR Led Hundreds of Protestors Outside Psychiatric Convention Demanding a Ban on Electroshock Treatment

Retrieved on: 
Tuesday, May 21, 2019
Psychiatry, Medicine, Human rights abuses, Electroconvulsive therapy, Neurotechnology, Treatment of bipolar disorder, Treatment of depression, ECT, Anti-psychiatry

CCHR reports that several psychiatrists crossed sides to join the protest, giving a "thumbs up" for a ban and agreeing with placards saying electroshock is "torture, not therapy."

Key Points: 
  • CCHR reports that several psychiatrists crossed sides to join the protest, giving a "thumbs up" for a ban and agreeing with placards saying electroshock is "torture, not therapy."
  • Jan Eastgate, President of CCHR International spoke of how CCHR helped obtain the precedent California law in 1976 that bans electroshock treatment on children and adolescents.
  • "This ban needs to be expanded to all age groups and worldwide," Eastgate added, "because electroshock causes harm, electroshock creates brain damage and electroshock ruins lives.
  • Human rights group loudly speaks out for nationwide ban on "torturous" electroshock treatment given 0-5 year olds, pregnant women, elderly, veterans

RidgeCrest Herbal's DreamOn Zen Wins Taste For Life Women's Essentials Award

Retrieved on: 
Friday, May 17, 2019
Branches of biology, Indian religions, Biology, Circadian rhythm, RTT, Treatment of bipolar disorder, Sleep, Melatonin, Zen, Hormone

This time it is their DreamOn Zen that has won the Taste For Life Women's Essentials Award in the category of Sleep.

Key Points: 
  • This time it is their DreamOn Zen that has won the Taste For Life Women's Essentials Award in the category of Sleep.
  • RidgeCrest Herbals' natural, gentle DreamOn Zen formula is a clever take on sleep management, working to help the body safely manage a good night's rest followed by a cheerful morning.
  • Unlike many natural sleep aids, DreamOn Zen does not contain melatonin, instead using herbs that promote relaxation and deep sleep so natural hormone production remains uninterrupted.
  • This is the first award for the well-deserving DreamOn Zen, which joins RidgeCrests' other award-winning products, including AnxietyFree, ClearLungs Immune, PhysiQOL, Essential Eyes, Thyroid Thrive, Hair Revive, and ClearLungs Sport.

NeuroStar® Advanced Therapy Survey Finds Majority of Americans Don't Feel Very Equipped to Discuss Depression With Loved Ones

Retrieved on: 
Tuesday, May 14, 2019
Psychiatry, Medicine, Health sciences, Neurotechnology, Treatment of bipolar disorder, Treatment of depression, Psychiatric diagnosis, Electroconvulsive therapy, Major depressive disorder, Therapy, Book:ECT

The survey was conducted online within the United States by The Harris Poll on behalf of NeuroStar Advanced Therapy among 2,010 U.S. adults.

Key Points: 
  • The survey was conducted online within the United States by The Harris Poll on behalf of NeuroStar Advanced Therapy among 2,010 U.S. adults.
  • Additionally, only about a quarter of Americans (27 percent) are aware that depression is a disorder of the brain.
  • * Unlike electroconvulsive therapy (ECT), NeuroStar is non-invasive and allows patients to resume daily activities immediately following treatment sessions.
  • In addition, there are programs in place, such as NeuroStar Reimbursement Support, to help patients and providers obtain coverage and reimbursement for NeuroStar Advanced Therapy.

Global Phototherapy Devices Market Forecast to 2028 by Application, End-user, Configuration and Region - ResearchAndMarkets.com

Retrieved on: 
Monday, April 29, 2019
Health, Medical devices, Medicine, Clinical medicine, Neonatology, Psoriasis, Health, Circadian rhythm, Light therapy, Treatment of bipolar disorder, Market

The "Global Phototherapy Devices Market: Focus on Applications, Configuration, Products, End-users, and 15 Countries Data - Analysis and Forecast, 2018-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Phototherapy Devices Market: Focus on Applications, Configuration, Products, End-users, and 15 Countries Data - Analysis and Forecast, 2018-2028" report has been added to ResearchAndMarkets.com's offering.
  • The global phototherapy devices market was valued at approximately $682.3 million in 2018 and is anticipated to reach $1.07 billion by 2028.
  • The phototherapy devices market is an emerging market in the medical device industry which consists of public and private companies.
  • What was the market value of the leading segments of the global phototherapy devices market in 2018?

Global Phototherapy Devices Market Report 2019

Retrieved on: 
Friday, April 26, 2019
Medicine, Clinical medicine, Psoriasis, Neonatology, Health, Circadian rhythm, Light therapy, Treatment of bipolar disorder, Market

The "Global Phototherapy Devices Market: Focus on Applications, Configuration, Products, End-users, and 15 Countries Data - Analysis and Forecast, 2018-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Phototherapy Devices Market: Focus on Applications, Configuration, Products, End-users, and 15 Countries Data - Analysis and Forecast, 2018-2028" report has been added to ResearchAndMarkets.com's offering.
  • The global phototherapy devices market was valued at approximately $682.3 million in 2018 and is anticipated to reach $1.07 billion by 2028.
  • The healthcare infrastructure in the developed market such as the U.S. and Germany has helped in the high adoption of phototherapy devices.
  • The global phototherapy market is currently at a niche stage considering there are products which are yet to be launched in the market during the forecast period.